Skip to Content Contact Us
diagyn at mixiii biomed conference 2019

Diagyn will participate in the MIXiii-Biomed Conference

May 16, 2019

Diagyn is taking part in the 18th National Life Science & Techology week, to be held on 14-16th May 2019

Read More
פטנט אימפרודיה1

A new Improdias` patent was granted in Israel

May 13, 2019

A Novel  Biomarker SNX9  For Chronic Inflammation and Associated Immunosuppression and a new regulator of T-Cell Expression and  receptor expression and function

Read More

GHP is paving the way for listing R&D companies in TASE

May 5, 2019

The Israel Securities Authority (ISA) announced on Sunday, May 5th 2019,  that it had approved the possibility of raising capital through the issue of Yahash to partnerships in research and development.


Read More
Improdia Board Of Directors

Prof. Dedi Meiri has been appointed to Improdia’s Scientific Advisory Board

March 15, 2019

Prof. Dedi Meiri, a lecturer and researcher in the field of medical cannabis at the Technion Institute of Technology, Haifa, and head of its Laboratory of Cancer Biology and Cannabinoid Research in the Biology Faculty, has been appointed as a member of the Scientific Advisory Board of Improdia.


Read More
Business Growth

AMENDIS signed a commercialization agreement with Yissum

February 12, 2019

Amndis has signed an Exclusive License Agreement with Yissum, the technology transfer company of The Hebrew University of Jerusalem. The company  is developing a genomic-measurement diagnostic test based on an AI learning machine for the purpose of preventing unnecessary life-threatening surgery for head-and-neck cancer patients..



Read More
GHP's companies

GHP’s Companies are at the forefront of technology

December 12, 2018

GHP’s portfolio includes companies whose source of technology is groundbreaking research from Israeli academic institutions, with an emphasis on life sciences and cancer-related developments in the early stages of clinical trials. The management strategy og GHP increases the value of the companies, focused on cancer research and personilized treatment. The group focuses on companies whose products require lenient regulatory processes, enabling short regulatory procedures, such as orphan drugs and compassionate medicines. 

Read More
Back top top